WO2004060280A3 - Methods and compositions for inhibiting the growth of hematopoietic malignant cells - Google Patents
Methods and compositions for inhibiting the growth of hematopoietic malignant cells Download PDFInfo
- Publication number
- WO2004060280A3 WO2004060280A3 PCT/US2003/039225 US0339225W WO2004060280A3 WO 2004060280 A3 WO2004060280 A3 WO 2004060280A3 US 0339225 W US0339225 W US 0339225W WO 2004060280 A3 WO2004060280 A3 WO 2004060280A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth
- malignant cells
- methods
- hematopoietic malignant
- hematopoietic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003296432A AU2003296432A1 (en) | 2002-12-18 | 2003-12-11 | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/321,587 US20030215445A1 (en) | 1997-05-23 | 2002-12-18 | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US10/321,587 | 2002-12-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004060280A2 WO2004060280A2 (en) | 2004-07-22 |
WO2004060280A3 true WO2004060280A3 (en) | 2005-06-16 |
Family
ID=32710755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/039225 WO2004060280A2 (en) | 2002-12-18 | 2003-12-11 | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
Country Status (3)
Country | Link |
---|---|
US (3) | US20030215445A1 (en) |
AU (1) | AU2003296432A1 (en) |
WO (1) | WO2004060280A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100111928A1 (en) * | 1997-05-23 | 2010-05-06 | A & G Pharmaceutical, Inc. | Methods and kits for diagnosis tumorgenicity |
US6309826B1 (en) * | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
FR2772047B1 (en) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
AU770896C (en) | 1998-09-29 | 2006-09-07 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
JP4488903B2 (en) * | 2003-02-26 | 2010-06-23 | エイアンドジー ファーマスーティカル インコーポレイテッド | Method for increasing B cell proliferation |
EP1601759A4 (en) * | 2003-03-07 | 2007-02-14 | Gamida Cell Ltd | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
ES2426916T3 (en) * | 2003-08-01 | 2013-10-25 | A & G Pharmaceutical, Inc. | Compositions and procedures to restore sensitivity to treatment with HER2 antagonists |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
SG11201404608WA (en) | 2012-02-13 | 2014-09-26 | Gamida Cell Ltd | Mesenchymal stem cells conditioned medium and methods of generating and using the same |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9443797B2 (en) * | 2012-09-14 | 2016-09-13 | STATS ChipPAC Pte. Ltd. | Semiconductor device having wire studs as vertical interconnect in FO-WLP |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5416192A (en) | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
WO1993015195A1 (en) | 1992-02-03 | 1993-08-05 | Samuel Solomon | Granulins from leukocytes |
AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
WO1995015084A1 (en) | 1993-11-30 | 1995-06-08 | Lxr Biotechnology Inc. | Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof |
US6881548B2 (en) | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
US20030215445A1 (en) | 1997-05-23 | 2003-11-20 | Ginette Serrero | Methods and compositions for inhibiting the growth of hematopoietic malignant cells |
US8512960B2 (en) | 1997-05-23 | 2013-08-20 | A&G Pharmaceutical, Inc. | 88kDa tumorigenic growth factor and antagonists |
US6309826B1 (en) | 1997-05-23 | 2001-10-30 | Ginette Serrero | 88kDa tumorigenic growth factor and antagonists |
US7091047B2 (en) | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
US6720159B1 (en) | 1997-12-16 | 2004-04-13 | A&G Pharmaceutical, Inc. | 88KDA tumorigenic growth factor and antagonists |
AU760466B2 (en) | 1999-02-26 | 2003-05-15 | Johns Hopkins University, The | A novel inhibitor of programmed cell death |
AU2001241877A1 (en) | 2000-02-28 | 2001-09-12 | The Regents Of The University Of California | Methods for detection and treatment of neural cancers |
ATE278421T1 (en) * | 2000-08-11 | 2004-10-15 | Wyeth Corp | METHOD FOR TREATING ESTROGEN RECEPTOR POSITIVE CARCINOMA |
AU2002213084A1 (en) | 2000-10-11 | 2002-04-22 | Avalon Pharmaceuticals | Cancer-linked genes as targets for chemotherapy |
US7411045B2 (en) | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
JP4488903B2 (en) | 2003-02-26 | 2010-06-23 | エイアンドジー ファーマスーティカル インコーポレイテッド | Method for increasing B cell proliferation |
WO2005000207A2 (en) | 2003-05-30 | 2005-01-06 | Medimmune, Inc. | Pcdgf receptor antibodies and methods of use thereof |
EP1644038A2 (en) | 2003-06-23 | 2006-04-12 | A & G Pharmaceuticals, Inc. | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
WO2005009363A2 (en) | 2003-07-21 | 2005-02-03 | Medimmune, Inc. | Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
ES2426916T3 (en) | 2003-08-01 | 2013-10-25 | A & G Pharmaceutical, Inc. | Compositions and procedures to restore sensitivity to treatment with HER2 antagonists |
WO2006044566A2 (en) | 2004-10-13 | 2006-04-27 | A & G Pharmaceutical, Inc. | Autocrine growth factor receptors and methods |
-
2002
- 2002-12-18 US US10/321,587 patent/US20030215445A1/en not_active Abandoned
-
2003
- 2003-12-11 AU AU2003296432A patent/AU2003296432A1/en not_active Abandoned
- 2003-12-11 WO PCT/US2003/039225 patent/WO2004060280A2/en not_active Application Discontinuation
-
2009
- 2009-04-08 US US12/420,676 patent/US8007997B2/en not_active Expired - Fee Related
-
2011
- 2011-08-29 US US13/220,307 patent/US8911950B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
LIAU ET AL.: "Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption", CANCER RES., vol. 60, no. 5, 1 March 2000 (2000-03-01), pages 1353 - 1360, XP002963369 * |
LU ET AL.: "Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF c DNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 8, 11 April 2000 (2000-04-11), pages 3993 - 3998, XP002963204 * |
Also Published As
Publication number | Publication date |
---|---|
US20120087918A1 (en) | 2012-04-12 |
US20100021475A1 (en) | 2010-01-28 |
US8911950B2 (en) | 2014-12-16 |
US20030215445A1 (en) | 2003-11-20 |
US8007997B2 (en) | 2011-08-30 |
AU2003296432A8 (en) | 2004-07-29 |
AU2003296432A1 (en) | 2004-07-29 |
WO2004060280A2 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004060280A3 (en) | Methods and compositions for inhibiting the growth of hematopoietic malignant cells | |
WO2003057837A8 (en) | Methods for using anti-muc18 antibodies | |
EP1470146B8 (en) | Antibodies against the muc18 antigen | |
EP1878725A3 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
WO2008063382A3 (en) | Antagonists of pcsk9 | |
WO2008057458A3 (en) | Antagonists of pcsk9 | |
WO2008133647A3 (en) | Antagonists of pcsk9 | |
WO2003057006A3 (en) | Use of antibodies against the muc18 antigen | |
HK1073660A1 (en) | Methods and compositions and rna interference | |
CA2492804A1 (en) | Novel inhibitors of kinases | |
WO2002028904A3 (en) | Human anti-cd40 antibodies | |
BRPI0413119A (en) | use of optimized adcc antibodies to treat debilitated patients | |
EP0954334A4 (en) | Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy | |
MX2007006754A (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders. | |
WO2006048877A3 (en) | Treatment of b-cell malignancies with fgfr3 inhibitors | |
PT1147103E (en) | FENANTRIDINE-N-OXIDES WITH PDE-IV INHIBITORS ACTIVITY | |
EP1736470A3 (en) | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | |
DK1147088T3 (en) | 6-arylphenanthridines with PDE-IV inhibitory activity | |
MXPA06007269A (en) | Compositions and methods for combined therapy of disease. | |
WO2007056331A3 (en) | Compositions and methods for inhibiting expression of factor v leiden mutant gene | |
WO2001005353A3 (en) | USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS | |
MXPA02003360A (en) | Transacylases of the paclitaxel biosynthetic pathway. | |
PL1687014T3 (en) | Use of additionally fermented distillers grains for preventing and/or treating increased blood sugar values | |
WO2002043648A8 (en) | Compounds active at the glucocorticoid receptor ii | |
AU2001261850A1 (en) | Crf receptor antagonists and methods relating thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |